Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,860 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency.
Stecklein SR, Barlow W, Pusztai L, Timms K, Kennedy R, Logan GE, Seitz R, Badve S, Gökmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi GN, Godwin AK, Thompson A, Hayes DF, Sharma P. Stecklein SR, et al. Among authors: kennedy r. JCO Precis Oncol. 2023 Sep;7:e2300197. doi: 10.1200/PO.23.00197. JCO Precis Oncol. 2023. PMID: 37972336
Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.
Walker SM, Knight LA, McCavigan AM, Logan GE, Berge V, Sherif A, Pandha H, Warren AY, Davidson C, Uprichard A, Blayney JK, Price B, Jellema GL, Steele CJ, Svindland A, McDade SS, Eden CG, Foster C, Mills IG, Neal DE, Mason MD, Kay EW, Waugh DJ, Harkin DP, Watson RW, Clarke NW, Kennedy RD. Walker SM, et al. Among authors: kennedy rd. Eur Urol. 2017 Oct;72(4):509-518. doi: 10.1016/j.eururo.2017.03.027. Epub 2017 Apr 10. Eur Urol. 2017. PMID: 28408174 Free article.
Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.
Turkington RC, Knight LA, Blayney JK, Secrier M, Douglas R, Parkes EE, Sutton EK, Stevenson L, McManus D, Halliday S, McCavigan AM, Logan GE, Walker SM, Steele CJ, Perner J, Bornschein J, MacRae S, Miremadi A, McCarron E, McQuaid S, Arthur K, James JA, Eatock MM, O'Neill R, Noble F, Underwood TJ, Harkin DP, Salto-Tellez M, Fitzgerald RC, Kennedy RD; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group. Turkington RC, et al. Among authors: kennedy rd. Gut. 2019 Nov;68(11):1918-1927. doi: 10.1136/gutjnl-2018-317624. Epub 2019 Mar 9. Gut. 2019. PMID: 30852560 Free PMC article.
A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer.
Wilkinson RDA, Burden RE, McDowell SH, McArt DG, McQuaid S, Bingham V, Williams R, Cox ÓT, O'Connor R, McCabe N, Kennedy RD, Buckley NE, Scott CJ. Wilkinson RDA, et al. Among authors: kennedy rd. J Oncol. 2019 Jun 27;2019:3980273. doi: 10.1155/2019/3980273. eCollection 2019. J Oncol. 2019. PMID: 31346333 Free PMC article.
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
Sharma P, Barlow WE, Godwin AK, Parkes EE, Knight LA, Walker SM, Kennedy RD, Harkin DP, Logan GE, Steele CJ, Lambe SM, Badve S, Gökmen-Polar Y, Pathak HB, Isakova K, Linden HM, Porter P, Pusztai L, Thompson AM, Tripathy D, Hortobagyi GN, Hayes DF. Sharma P, et al. J Clin Oncol. 2019 Dec 20;37(36):3484-3492. doi: 10.1200/JCO.19.00693. Epub 2019 Oct 28. J Clin Oncol. 2019. PMID: 31657982 Free PMC article.
In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.
Malla SB, Fisher DJ, Domingo E, Blake A, Hassanieh S, Redmond KL, Richman SD, Youdell M, Walker SM, Logan GE, Chatzipli A, Amirkhah R, Humphries MP, Craig SG, McDermott U, Seymour MT, Morton DG, Quirke P, West NP, Salto-Tellez M, Kennedy RD, Johnston PG, Tomlinson I, Koelzer VH, Campo L, Kaplan RS, Longley DB, Lawler M, Maughan TS, Brown LC, Dunne PD; S:CORT consortium. Malla SB, et al. Among authors: kennedy rd. Clin Cancer Res. 2021 Jan 1;27(1):288-300. doi: 10.1158/1078-0432.CCR-20-3237. Epub 2020 Oct 7. Clin Cancer Res. 2021. PMID: 33028592 Free PMC article.
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.
Parkes EE, Savage KI, Lioe T, Boyd C, Halliday S, Walker SM, Lowry K, Knight L, Buckley NE, Grogan A, Logan GE, Clayton A, Hurwitz J, Kirk SJ, Xu J, Sidi FA, Humphries MP, Bingham V; Neo-DDIR Investigators; James JA, James CR, Paul Harkin D, Kennedy RD, McIntosh SA. Parkes EE, et al. Among authors: kennedy rd. Br J Cancer. 2022 Feb;126(2):247-258. doi: 10.1038/s41416-021-01599-0. Epub 2021 Nov 2. Br J Cancer. 2022. PMID: 34728791 Free PMC article.
Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.
Jain S, Lyons CA, Walker SM, McQuaid S, Hynes SO, Mitchell DM, Pang B, Logan GE, McCavigan AM, O'Rourke D, McArt DG, McDade SS, Mills IG, Prise KM, Knight LA, Steele CJ, Medlow PW, Berge V, Katz B, Loblaw DA, Harkin DP, James JA, O'Sullivan JM, Kennedy RD, Waugh DJ. Jain S, et al. Among authors: kennedy rd. Ann Oncol. 2018 Jan 1;29(1):215-222. doi: 10.1093/annonc/mdx637. Ann Oncol. 2018. PMID: 29045551 Free PMC article.
2,860 results